Cargando…

Preferences for a COVID-19 vaccine in Australia

In absence of a COVID-19 vaccine, testing, contact tracing and social restrictions are among the most powerful strategies adopted around the world to slow down the spread of the pandemic. Citizens of most countries are suffering major physical, psychological and economic distress. At this stage, a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Borriello, Antonio, Master, Daniel, Pellegrini, Andrea, Rose, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832016/
https://www.ncbi.nlm.nih.gov/pubmed/33358265
http://dx.doi.org/10.1016/j.vaccine.2020.12.032
_version_ 1783641742713552896
author Borriello, Antonio
Master, Daniel
Pellegrini, Andrea
Rose, John M.
author_facet Borriello, Antonio
Master, Daniel
Pellegrini, Andrea
Rose, John M.
author_sort Borriello, Antonio
collection PubMed
description In absence of a COVID-19 vaccine, testing, contact tracing and social restrictions are among the most powerful strategies adopted around the world to slow down the spread of the pandemic. Citizens of most countries are suffering major physical, psychological and economic distress. At this stage, a safe and effective COVID-19 vaccine is the most sustainable option to manage the current pandemic. However, vaccine hesitancy by even a small subset of the population can undermine the success of this strategy. The objective of this research is to investigate the vaccine characteristics that matter the most to Australian citizens and to explore the potential uptake of a COVID-19 vaccine in Australia. Through a stated preference experiment, preferences towards a COVID-19 vaccine of 2136 residents of the Australian states and territories were collected and analysed via a latent class model. Results show that preferences for mild adverse cases, mode of administration, location of administration, price and effectiveness are heterogeneous. Conversely, preferences for immediacy and severe reactions are homogeneous, with respondents preferring a shorter period until vaccine is available and lower instances of severe side effects. The expected uptake of the vaccine is estimated under three different scenarios, with the value of 86% obtained for an average scenario. By calculating individual preferences, the willingness to pay is estimated for immediacy, effectiveness, mild and severe side effects.
format Online
Article
Text
id pubmed-7832016
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-78320162021-01-26 Preferences for a COVID-19 vaccine in Australia Borriello, Antonio Master, Daniel Pellegrini, Andrea Rose, John M. Vaccine Article In absence of a COVID-19 vaccine, testing, contact tracing and social restrictions are among the most powerful strategies adopted around the world to slow down the spread of the pandemic. Citizens of most countries are suffering major physical, psychological and economic distress. At this stage, a safe and effective COVID-19 vaccine is the most sustainable option to manage the current pandemic. However, vaccine hesitancy by even a small subset of the population can undermine the success of this strategy. The objective of this research is to investigate the vaccine characteristics that matter the most to Australian citizens and to explore the potential uptake of a COVID-19 vaccine in Australia. Through a stated preference experiment, preferences towards a COVID-19 vaccine of 2136 residents of the Australian states and territories were collected and analysed via a latent class model. Results show that preferences for mild adverse cases, mode of administration, location of administration, price and effectiveness are heterogeneous. Conversely, preferences for immediacy and severe reactions are homogeneous, with respondents preferring a shorter period until vaccine is available and lower instances of severe side effects. The expected uptake of the vaccine is estimated under three different scenarios, with the value of 86% obtained for an average scenario. By calculating individual preferences, the willingness to pay is estimated for immediacy, effectiveness, mild and severe side effects. Elsevier Ltd. 2021-01-15 2020-12-16 /pmc/articles/PMC7832016/ /pubmed/33358265 http://dx.doi.org/10.1016/j.vaccine.2020.12.032 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Borriello, Antonio
Master, Daniel
Pellegrini, Andrea
Rose, John M.
Preferences for a COVID-19 vaccine in Australia
title Preferences for a COVID-19 vaccine in Australia
title_full Preferences for a COVID-19 vaccine in Australia
title_fullStr Preferences for a COVID-19 vaccine in Australia
title_full_unstemmed Preferences for a COVID-19 vaccine in Australia
title_short Preferences for a COVID-19 vaccine in Australia
title_sort preferences for a covid-19 vaccine in australia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832016/
https://www.ncbi.nlm.nih.gov/pubmed/33358265
http://dx.doi.org/10.1016/j.vaccine.2020.12.032
work_keys_str_mv AT borrielloantonio preferencesforacovid19vaccineinaustralia
AT masterdaniel preferencesforacovid19vaccineinaustralia
AT pellegriniandrea preferencesforacovid19vaccineinaustralia
AT rosejohnm preferencesforacovid19vaccineinaustralia